Analysis of the dose-sparing effect of adjuvanted Sabin-inactivated poliovirus vaccine (sIPV)

References

• Home C. Laboratory surveillance for wild and vaccine-derived polioviruses--worldwide, January 2007-June 2008. Mmwr Morbidity & Mortality Weekly Report. 2008;57:967.
   Google Scholar
• Roberts L. A one-two punch against polio. Petroleum Rock Mechanics. 2014;345:63–76.
   Google Scholar
• Bahl S, Bhatnagar P, Sutter RW, Roesel S, Zaffran M. Global Polio Eradication - Way Ahead. The Indian Journal of Pediatrics. 2018;85:124–131. doi:10.1007/s12098-017-2586-8. PMID:29302865.
   PubMed Web of Science ®Google Scholar
• Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-Derived Polioviruses. Journal of Infectious Diseases. 2014;210(Suppl 1):S283. doi:10.1093/infdis/jiu295. PMID:25316847.
   PubMed Web of Science ®Google Scholar
• Platt LR, Estívariz CF, Sutter RW. Vaccine-Associated Paralytic Poliomyelitis: A Review of the Epidemiology and Estimation of the Global Burden. Journal of Infectious Diseases. 2014;210(Suppl 1):S380. doi:10.1093/infdis/jiu184. PMID:25316859.
   PubMed Web of Science ®Google Scholar
• Initiative GPE. Polio Eradication and Endgame Strategic Plan 2013–2018. Immunization Programs. 2013. http://www.who.int/immunization/sage/meetings/2012/november/1_DRAFTGPEI_EndgameStrategicPlan23Oct12.pdf.
   Google Scholar
• http://www.who.int/wer/2012/wer8721.pdf?ua=1._Weekly_epidemiological_record. 2012.
   Google Scholar
• Okayasu H, Sutter RW, Jafari HS, Takane M, Aylward RB. Affordable inactivated poliovirus vaccine: strategies and progress. Journal of Infectious Diseases. 2014;210(Suppl 1):S459. doi:10.1093/infdis/jiu128. PMID:25316868.
   PubMedGoogle Scholar
• Shulman LM, Manor Y & Sofer D. Poliovirus vaccine and vaccine-derived polioviruses. N Engl J Med. 2010;363:1870–1. doi:10.1056/NEJMc1009551. PMID:21047241.
   PubMedGoogle Scholar
• Cadorna-Carlos J, Vidor E, Bonnet MC. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. Int J Infect Dis. 2012;16:110–6. doi:10.1016/j.ijid.2011.10.002.
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemañi N, Garcia G, Fonseca M, Hung LH, Kahn AL, et al. Priming after a fractional dose of inactivated poliovirus vaccine. New England Journal of Medicine. 2013;368:416–24. doi:10.1056/NEJMoa1202541. PMID:23363495.
   PubMed Web of Science ®Google Scholar
• Anand A, Zaman K, Estívariz CF, Yunus M, Gary HE, Weldon WC, Bari TI, Steven Oberste M, Wassilak SG, Luby SP, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine. 2015;33:6816. doi:10.1016/j.vaccine.2015.09.039. PMID:26476367.
   PubMed Web of Science ®Google Scholar
• Resik S, Tejeda A2, Diaz M, Okayasu H, Sein C, Molodecky NA, Fonseca M, Alemany N, Garcia G, Hung LH, et al. Boosting Immune Responses Following Fractional-Dose Inactivated Poliovirus Vaccine: A Randomized, Controlled Trial. Journal of Infectious Diseases. 2017;215:175. PMID:28073858.
   PubMed Web of Science ®Google Scholar
• Ma L, Cai W, Sun M, Cun Y, Zhou J, Liu J, Hu W, Zhang X, Song S, Jiang S, et al. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats. Human Vaccines. 2016;12:3125–31. doi:10.1080/21645515.2016.1214347.
   Web of Science ®Google Scholar
• Giarolasilva S, Coelho-Dos-Reis JGA, Mourão MM, Campi-Azevedo AC, Nakagaki Silva EE, Luiza-Silva M, Martins MA, Silveira-Cassette ACO, Batista MA, Peruhype-Magalhães V, et al. Distinct patterns of cellular immune response elicited by influenza non-adjuvanted and AS03-adjuvanted monovalent H1N1(pdm09) vaccine. Antiviral Research. 2017;144:70–82. doi:10.1016/j.antiviral.2017.05.009. PMID:28549970.
   PubMed Web of Science ®Google Scholar
• Durando P, Iudici R, Alicino C, Alberti M, de Florentis D, Ansaldi F, Icardi G. Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine. Human Vaccines. 2011;7(Suppl):29. doi:10.4161/hv.7.0.14560. PMID:21245655.
   PubMedGoogle Scholar
• Patel S, Faraj Y, Duso DK, Reiley WW, Karlsson EA, Schultz-Cherry S, Vajdy M. Comparative Safety and Efficacy Profile of a Novel Oil in Water Vaccine Adjuvant Comprising Vitamins A and E and a Catechin in Protective Anti-Influenza Immunity. Nutrients. 2017;9:516. doi:10.3390/nu9050516.
   Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatric Infectious Disease Journal. 2009;28:563. doi:10.1097/INF.0b013e31819d6394. PMID:19561422.
   PubMed Web of Science ®Google Scholar
• Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, Lattanzi M, Del Giudice G, Rappuoli R, Golding H. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Science Translational Medicine. 2011;3:85ra48. doi:10.1126/scitranslmed.3002336. PMID:21632986.
   PubMed Web of Science ®Google Scholar
• Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine. 2013;31:1298. doi:10.1016/j.vaccine.2012.12.076. PMID:23313617.
   PubMed Web of Science ®Google Scholar
• Ghendon Y, Markushin S, Akopova I, Koptiaeva I & Krivtsov G. Chitosan as an adjuvant for poliovaccine. Journal of Medical Virology. 2011;83:847–52. doi:10.1002/jmv.22030. PMID:21412793.
   PubMed Web of Science ®Google Scholar
• Verdijk P, Rots NY, van Oijen MG, Weldon WC, Oberste MS, Okayasu H, Sutter RW, Bakker WA. Safety and immunogenicity of a primary series of Sabin-IPV with and without aluminum hydroxide in infants. Vaccine. 2014;32:4938–44. doi:10.1016/j.vaccine.2014.07.029. PMID:25043278.
   PubMed Web of Science ®Google Scholar
• Rivera L, Pedersen RS, Peña L, Olsen KJ, Andreasen LV, Kromann I, Nielsen PI, Sørensen C, Dietrich J, Bandyopadhyay AS, et al. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial. The Lancet Infectious Diseases. 2017;17:745–53. doi:10.1016/S1473-3099(17)30177-9. PMID:28454674.
   PubMed Web of Science ®Google Scholar
• Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, Planty C, Elouahabi A, Harvengt P, Carlsen H, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine. 2011;29:2461–73. doi:10.1016/j.vaccine.2011.01.011. PMID:21256188.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, et al. A Toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740. doi:10.1038/35047123. PMID:11130078.
   PubMed Web of Science ®Google Scholar
• Ishii KJ & Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. Journal of Clinical Immunology. 2007;27:363. doi:10.1007/s10875-007-9087-x. PMID:17370119.
   PubMed Web of Science ®Google Scholar
• Minang JT, Inglefield JR, Harris AM, Lathey JL, Alleva DG, Sweeney DL, Hopkins RJ, Lacy MJ, Bernton EW. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909). Vaccine. 2014;32:6847–54. doi:10.1016/j.vaccine.2014.01.096. PMID:24530403.
   PubMed Web of Science ®Google Scholar
• Hopkins RJ, Kalsi G, Montalvo-Lugo VM, Sharma M, Wu Y, Muse DD, Sheldon EA, Hampel FC, Lemiale L. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults. Vaccine. 2016;34:2096–105. doi:10.1016/j.vaccine.2016.03.006. PMID:26979136.
   PubMed Web of Science ®Google Scholar
• Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS. A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. Journal of the National Cancer Institute. 1976;57:599–602. doi:10.1093/jnci/57.3.599. PMID:978771.
   PubMedGoogle Scholar
• Zhang Y, Zhang S, Li W, Hu Y, Zhao J, Liu F, Lin H, Liu Y, Wang L, Xu S, Hu R, et al. A novel rabies vaccine based-on toll-like receptor 3 (TLR3) agonist PIKA adjuvant exhibiting excellent safety and efficacy in animal studies. Virology. 2016;489:165. doi:10.1016/j.virol.2015.10.029. PMID:26765968.
   PubMed Web of Science ®Google Scholar
• Zhang A, Lai H, Xu J, Huang W, Liu Y, Zhao D, Chen R. Evaluation of the Protective Efficacy of Poly I:C as an Adjuvant for H9N2 Subtype Avian Influenza Inactivated Vaccine and Its Mechanism of Action in Ducks. Plos One. 2017;12:e0170681. doi:10.1371/journal.pone.0170681. PMID:28135294.
   PubMed Web of Science ®Google Scholar
• Moriyama M, Chino S, Ichinohe T. Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge. Vaccine. 2017;35:1001–7. doi:10.1016/j.vaccine.2017.01.025. PMID:28111142.
   PubMed Web of Science ®Google Scholar
• Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Review of Vaccines. 2012;11:349–66. doi:10.1586/erv.11.192. PMID:22380826.
   PubMed Web of Science ®Google Scholar
• Hartmann G, Weiner GJ, Krieg AM. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A. 1999;96:9305–10. doi:10.1073/pnas.96.16.9305. PMID:10430938.
   PubMed Web of Science ®Google Scholar
• He B, Qiao X & Cerutti A. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. Journal of Immunology. 2004;173:4479. doi:10.4049/jimmunol.173.7.4479.
   PubMed Web of Science ®Google Scholar
• Wang X, Bao M, Wan M, Wei H, Wang L, Yu H, Zhang X, Yu Y, Wang L. A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine. Vaccine. 2008;26:1893–901. doi:10.1016/j.vaccine.2008.01.043. PMID:18321616.
   PubMed Web of Science ®Google Scholar
• TR M & S S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunology today. 1996;17:138. doi:10.1016/0167-5699(96)80606-2. PMID:8820272.
   PubMedGoogle Scholar
• Broere F, Apasov SG, Sitkovsky MV, Eden WV. A2 T cell subsets and T cell-mediated immunity. Principles of Immunopharmacology. Birkhäuser Basel. 2011;15–27.
   Google Scholar
• DL-alpha-Tocopherol. http://www.sigmaaldrich.com/catalog/product/supelco/47786?lang=en&region=US.
   Google Scholar
• Squalene. http://www.sigmaaldrich.com/catalog/substance/squalene4107211102411?lang=en&region=US.
   Google Scholar
• Polysorbate80. http://www.sigmaaldrich.com/catalog/substance/polysorbate8012345900565611?lang=en&region=US.
   Google Scholar
• Annex 2: Guidelines for the safe production and quality control of inactivated poliomyelitis vaccine manufactured from wild polioviruses (Addendum, 2003, to the Recommendations for the Production and Quality Control of Poliomyelitis Vaccine. Who Technical Report No. 926, 2004.
   Google Scholar
• Haensler J. Manufacture of Oil-in-Water Emulsion Adjuvants. New York: Springer; 2017.
   Google Scholar
• Zhou X, Wei H, Sun P, Wu X, Wan M, Zhang P, Guo S, Zhao T, Yu Y, Wang L. Recombinant hepatitis B virus surface antigen formulated with B-type CpG oligodeoxynucleotide induces therapeutic immunity against hepatitis B virus surface antigen-expressing liver cancer cells in mice. Cancer Biotherapy & Radiopharmaceuticals. 2012;27:234. doi:10.1089/cbr.2011.1127.
   PubMed Web of Science ®Google Scholar
• Reed LJ, Muench H. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS. American Journal of Tropical Medicine & Hygiene. 1938;27.
   Google Scholar